Lupin secures U.S. FDA approval for interchangeable biosimilar Ranibizumab

Ranluspec is the only interchangeable ranibizumab biosimilar approved in the United States in both vial and pre-filled syringe (PFS) presentations

Healthcare policymakers lay thrust on genetic screening and indigenous therapies for rare diseases

Under the new policy, financial assistance has been increased to Rs 50 lakh per patient to improve treatment access

Patient-centric innovation driving fight against neglected diseases: Sanjay Sarin, Continental Lead Asia and South Asia Director, DNDi

While Drugs for Neglected Diseases initiative (DNDi) drives the R&D for neglected diseases, we collaborate with pharmaceutical companies at multiple stages, including sourcing promising molecules

Lupin wins USFDA nod for generic Dapagliflozin tablets

Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market

NATCO announces launch of Pomalidomide capsules in US

It is also approved for?AIDS-related Kaposi sarcoma?after failure of highly active antiretroviral therapy, as well as for HIV-negative adult patients with Kaposi sarcoma

Budget 2026 -27: Pharma sector cheers Rs. 10,000 crore Biopharma plan

The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave

Zydus Partners with Bioeq for US commercialisation rights for Nufymco

NUFYMCO BLA has been approved by the USFDA

Alkem Foundation and IIT Bombay collaborate to set up advanced research centre for immuno-therapeutics, regenerative medicines

This is the first industry-academia collaboration in the country, initiated through the CSR route, for advancing research in the areas of immuno-therapeutics and regenerative medicines

Biocon gets 1 USFDA observation for Cranbury site

The Cranbury facility represents a strategic advancement of the company's operations in the Unted States

Biocon inaugurates first US manufacturing facility in New Jersey